Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Danegaptide for primary percutaneous coronary intervention in acute myocardial infarction patients: a phase 2 randomised clinical trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Valve regurgitation in patients surviving endocarditis and the subsequent risk of heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Alcohol septal ablation in patients with severe septal hypertrophy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Interaction of ischaemic postconditioning and thrombectomy in patients with ST-elevation myocardial infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Outcome after heart-lung or lung transplantation in patients with Eisenmenger syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Significantly increased risk of all-cause mortality among cardiac patients feeling lonely

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Incidence of acute myocardial infarction-related cardiogenic shock during corona virus disease 19 (COVID-19) pandemic

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Hypertension, cardiovascular disease and cause of death in Danish living kidney donors: matched cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Catheter ablation and mortality, stroke and heart failure readmission with atrial fibrillation

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVES: Reperfusion immediately after reopening of the infarct-related artery in ST-segment elevation myocardial infarction (STEMI) may cause myocardial damage in addition to the ischaemic insult (reperfusion injury). The gap junction modulating peptide danegaptide has in animal models reduced this injury. We evaluated the effect of danegaptide on myocardial salvage in patients with STEMI.

METHODS: In addition to primary percutaneous coronary intervention in STEMI patients with thrombolysis in myocardial infarction flow 0-1, single vessel disease and ischaemia time less than 6 hours, we tested, in a clinical proof-of-concept study, the therapeutic potential of danegaptide at two-dose levels. Primary outcome was myocardial salvage evaluated by cardiac MRI after 3 months.

RESULTS: From November 2013 to August 2015, a total of 585 patients were randomly enrolled in the trial. Imaging criteria were fulfilled for 79 (high dose), 80 (low dose) and 84 (placebo) patients eligible for the per-protocol analysis. Danegaptide did not affect the myocardial salvage index (danegaptide high (63.9±14.9), danegaptide low (65.6±15.6) and control (66.7±11.7), P=0.40), final infarct size (danegaptide high (19.6±11.4 g), danegaptide low (18.6±9.6 g) and control (21.4±15.0 g), P=0.88) or left ventricular ejection fraction (danegaptide high (53.9%±9.5%), danegaptide low (52.7%±10.3%) and control (52.1%±10.9%), P=0.64). There was no difference between groups with regard to clinical outcome.

CONCLUSIONS: Administration of danegaptide to patients with STEMI did not improve myocardial salvage.

TRIAL REGISTRATION NUMBER: NCT01977755; Pre-results.

Original languageEnglish
JournalHeart (British Cardiac Society)
Volume104
Issue number19
Pages (from-to)1593-1599
Number of pages7
ISSN1355-6037
DOIs
Publication statusPublished - Oct 2018

ID: 56239750